Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on a phase 2 ...

Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic ...

Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator ...

In the phase 2 trial, efficacy was also seen in patients with non-atopic chronic hand eczema treated with the oral JAK ...

Biogen announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (part A) of investigational therapy, ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs ...

Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...

The company launched a Phase 2 Long COVID study to evaluate whether immune activation with Anktiva can improve recovery by ...

Cybin Inc (NASDAQ:HELP) is among the best psychedelic stocks to buy in 2026. Toronto, Canada-based Cybin Inc. is also known ...

ImmunoSarc2 (Cohort 7a): A Spanish Sarcoma Group (GEIS) phase Ib trial of epirubicin and ifosfamide plus nivolumab in first line of advanced undifferentiated pleomorphic sarcoma (UPS). This is an ASCO ...

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...